Adagene (ADAG) Competitors $2.18 -0.19 (-8.02%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.18 +0.00 (+0.23%) As of 08/7/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. CAPR, HUMA, KOD, AURA, ARCT, ABEO, NBTX, RNAC, RCKT, and CADLShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Capricor Therapeutics (CAPR), Humacyte (HUMA), Kodiak Sciences (KOD), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Abeona Therapeutics (ABEO), Nanobiotix (NBTX), Cartesian Therapeutics (RNAC), Rocket Pharmaceuticals (RCKT), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Capricor Therapeutics Humacyte Kodiak Sciences Aura Biosciences Arcturus Therapeutics Abeona Therapeutics Nanobiotix Cartesian Therapeutics Rocket Pharmaceuticals Candel Therapeutics Adagene (NASDAQ:ADAG) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Do insiders & institutionals have more ownership in ADAG or CAPR? 9.5% of Adagene shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 10.5% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ADAG or CAPR more profitable? Adagene has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -181.71%. Adagene's return on equity of 0.00% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Capricor Therapeutics -181.71%-62.42%-48.36% Do analysts prefer ADAG or CAPR? Adagene presently has a consensus target price of $7.50, indicating a potential upside of 244.04%. Capricor Therapeutics has a consensus target price of $22.56, indicating a potential upside of 179.50%. Given Adagene's higher probable upside, research analysts clearly believe Adagene is more favorable than Capricor Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has more risk & volatility, ADAG or CAPR? Adagene has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Which has stronger valuation and earnings, ADAG or CAPR? Adagene has higher earnings, but lower revenue than Capricor Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K1,027.00-$33.42MN/AN/ACapricor Therapeutics$22.27M16.55-$40.47M-$1.42-5.68 Does the media refer more to ADAG or CAPR? In the previous week, Capricor Therapeutics had 19 more articles in the media than Adagene. MarketBeat recorded 25 mentions for Capricor Therapeutics and 6 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Capricor Therapeutics' score of 0.09 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAdagene beats Capricor Therapeutics on 9 of the 14 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.65M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E RatioN/A17.9729.9425.14Price / Sales1,027.00262.51398.9486.71Price / CashN/A41.8335.9458.58Price / Book1.917.238.105.59Net Income-$33.42M-$54.43M$3.26B$265.48M7 Day Performance13.54%0.22%0.68%1.22%1 Month Performance15.34%5.59%2.46%0.39%1 Year Performance-11.02%9.98%27.69%23.47% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.944 of 5 stars$2.18-8.0%$7.50+244.0%-5.2%$111.65M$100K0.00260News CoverageAnalyst ForecastCAPRCapricor Therapeutics3.5897 of 5 stars$7.68-2.8%$22.56+193.7%+126.7%$360.85M$22.27M-5.41101Trending NewsHUMAHumacyte1.8981 of 5 stars$2.26-0.9%$11.71+418.3%-68.5%$353.67M$1.57M-3.28150Upcoming EarningsKODKodiak Sciences2.4248 of 5 stars$7.31+9.9%$9.00+23.1%+251.9%$350.88MN/A-2.0190Upcoming EarningsAURAAura Biosciences1.969 of 5 stars$6.61-1.9%$22.00+232.8%-20.0%$338.81MN/A-3.4850News CoverageUpcoming EarningsARCTArcturus Therapeutics2.8356 of 5 stars$12.20-0.8%$54.00+342.6%-36.0%$333.58M$152.31M-4.82180News CoveragePositive NewsUpcoming EarningsABEOAbeona Therapeutics3.8846 of 5 stars$6.42-1.1%$19.25+199.8%+41.9%$332.01M$3.50M-5.0690Upcoming EarningsNBTXNanobiotix0.8266 of 5 stars$6.80flat$8.00+17.6%+53.6%$320.51M$39.18M0.00100Gap UpHigh Trading VolumeRNACCartesian Therapeutics2.1165 of 5 stars$12.48+1.2%$40.00+220.5%-25.8%$320.02M$38.91M-0.2464News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8419 of 5 stars$3.07+2.7%$17.87+482.0%-83.7%$319.29MN/A-1.17240Trending NewsEarnings ReportCADLCandel Therapeutics2.5734 of 5 stars$6.31+0.3%$22.00+248.7%+16.3%$315.15MN/A-4.7160Upcoming Earnings Related Companies and Tools Related Companies CAPR Competitors HUMA Competitors KOD Competitors AURA Competitors ARCT Competitors ABEO Competitors NBTX Competitors RNAC Competitors RCKT Competitors CADL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
